1. Home
  2. FULC

FULC

Fulcrum Therapeutics Inc.

Logo Fulcrum Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Founded: 2015 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 489.9M IPO Year: 2019
Target Price: $13.17 AVG Volume (30 days): 654.3K
Analyst Decision: Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.59 EPS Growth: N/A
52 Week Low/High: $2.39 - $13.70 Next Earning Date: 05-13-2024
Revenue: $2,805,000 Revenue Growth: -55.77%
Revenue Growth (this year): -30.3% Revenue Growth (next year): 595.81%

Share on Social Networks: